Sign In
Buy LIFE
$16.89
-0.375 (-2.17%)
At Close: Jun 03, 2026
5 Top Stocks to Play Earnings Beat Potential
09:01am, Monday, 04'th Sep 2023
These top-ranked stocks are likely to beat on the bottom line in their upcoming releases. Tap American Woodmark (AMWD), Skechers (SKX), Workday (WDAY), aTyr Pharma (LIFE) and Modine Manufacturing (MOD
Down -9.64% in 4 Weeks, Here's Why You Should You Buy the Dip in Atyr Pharma (LIFE)
11:16am, Wednesday, 30'th Aug 2023
Atyr Pharma (LIFE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revisi
aTyr Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference
08:00am, Thursday, 24'th Aug 2023
SAN DIEGO, Aug. 24, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA
5 Top Stocks Likely to Top Earnings Estimates
09:34am, Friday, 18'th Aug 2023
Top-ranked stocks Yum China (YUMC), Amazon.com (AMZN), Workday (WDAY), aTyr Pharma (LIFE) and D.R. Horton (DHI) are likely to beat on the bottom line in their upcoming releases.
Atyr Pharma (LIFE) Reports Q2 Loss, Lags Revenue Estimates
06:59pm, Wednesday, 09'th Aug 2023
Atyr Pharma (LIFE) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.44 per share a year ago.
7 Growth Stocks That AI Predicts Will Deliver Triple-Digit Returns in 2023
07:00am, Wednesday, 28'th Jun 2023
This year's rally has seen many growth stocks deliver triple-digit returns, especially ones from the AI sector. Investors are willing to take more risks in 2023, and growth names have strongly trended
Presentations highlight efzofitimod's novel myeloid-cell focused mechanism and current Phase 3 EFZO-FIT ™ study in pulmonary sarcoidosis .
aTyr Pharma to Present at the 2023 Jefferies Healthcare Conference
08:00am, Thursday, 25'th May 2023
SAN DIEGO, May 25, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA s
aTyr Pharma to Present at the 2023 RBC Capital Markets Global Healthcare Conference
04:00pm, Thursday, 11'th May 2023
SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA s
Atyr Pharma (LIFE) Reports Q1 Loss, Misses Revenue Estimates
06:20pm, Tuesday, 09'th May 2023
Atyr Pharma (LIFE) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of $0.44 per share a year ago.
aTyr Pharma, Inc. (LIFE) Q4 2022 Earnings Call Transcript
05:12pm, Friday, 10'th Mar 2023
aTyr Pharma, Inc. (NASDAQ:LIFE ) Q4 2022 Earnings Conference Call March 9, 2023 5:00 PM ET Company Participants Ashlee Dunston - Director, Investor Relations & Corporate Communications Sanjay Shukla -
Where aTyr Pharma Stands With Analysts
03:01pm, Friday, 10'th Mar 2023 Benzinga
Analysts have provided the following ratings for aTyr Pharma (NASDAQ:LIFE) within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
3
2
0
0
0
Las
Atyr Pharma (LIFE) Reports Q4 Loss, Tops Revenue Estimates
10:15pm, Thursday, 09'th Mar 2023 Zacks Investment Research
Atyr Pharma (LIFE) delivered earnings and revenue surprises of 45.83% and 592.40%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
aTyr Pharma Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate Update
09:00pm, Thursday, 09'th Mar 2023 GlobeNewswire Inc.
Phase 3 EFZO-FIT™ study of efzofitimod in patients with pulmonary sarcoidosis enrolling in the U.S., Europe and Japan.
Atyr Pharma (LIFE) Reports Q4 Loss, Tops Revenue Estimates
06:19pm, Thursday, 09'th Mar 2023
Atyr Pharma (LIFE) delivered earnings and revenue surprises of 45.83% and 592.40%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
